{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:48:38Z","timestamp":1768391318585,"version":"3.49.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A 36-year-old man presented with a 1-month history of abdominal distension and a 3-day palpable mass. Imaging demonstrated a 20-cm left renal tumor with adjacent organ infiltration and suspicious lymphadenopathy, radiologically suggestive of sarcoma or advanced malignancy. He underwent radical en bloc resection including left nephrectomy, distal pancreatectomy, splenectomy, and partial colectomy due to tumor invasion of the pancreatic tail, splenic vessels, and descending colon mesentery. Histopathology confirmed Xp11.2 translocation\/TFE3 gene fusion renal cell carcinoma. Surveillance MRI at 3 months postoperatively revealed local recurrence, prompting combination therapy with sunitinib (VEGF inhibitor) and sintilimab (anti-PD-1 antibody). Follow-up imaging demonstrated significant regression at 1 month, with no evidence of disease progression at 12-month reassessment.<\/jats:p>","DOI":"10.3389\/fonc.2025.1709543","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:34:31Z","timestamp":1768372471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success"],"prefix":"10.3389","volume":"15","author":[{"given":"Bohan","family":"Luo","sequence":"first","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Zigong Fourth People\u2019s Hospital","place":["Zigong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206686","article-title":"A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)","volume":"22","author":"Argani","year":"2003","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1183","article-title":"Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry","volume":"15","author":"Komai","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12894-015-0055\u20130","article-title":"Xp11.2 translocation renal cell carcinomas in young adults","volume":"15","author":"Xu","year":"2025","journal-title":"BMC Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12894-022-01060\u20131","article-title":"Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation\/TFE3 gene fusion renal cell carcinomas","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20240985","DOI":"10.1515\/med-2024-0985","article-title":"Four years of natural progressive course: A rare case report of juvenile Xp11.2 translocations renal cell carcinoma with TFE3 gene fusion","volume":"19","author":"Hu","year":"2024","journal-title":"Open Med (Warsaw Poland)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/PDM.0b013e31820e9c67","article-title":"Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas","volume":"20","author":"Mosquera","year":"2011","journal-title":"Diagn Mol Pathol"},{"key":"B9","article-title":"Hinyokika kiyo","volume":"57","author":"Horie","year":"2011","journal-title":"Acta urologica Japonica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.12.038","article-title":"En bloc mobilization of the pancreas and spleen to facilitate resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen: techniques derived from multivisceral transplantation","volume":"55","author":"Ciancio","year":"2009","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2015.12.007","article-title":"Clear cell papillary renal cell carcinoma as part of histologically discordant multifocal renal cell carcinoma: A case report and review of literature","volume":"212","author":"Shao","year":"2016","journal-title":"Pathology Res Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1066896910375565","article-title":"Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis","volume":"18","author":"Rao","year":"2010","journal-title":"Int J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e8ce5b","article-title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23007","article-title":"Translocation carcinomas of the kidney","volume":"61","author":"Argani","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00343-2","article-title":"First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1709543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:34:32Z","timestamp":1768372472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1709543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1709543"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1709543","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1709543"}}